I have written much about the need to begin studies of both timing and combining of the many new treatments we have recently developed for the treatment of advanced prostate cancer. With the FDA approval of Provenge, Zytiga, Jevtana, Xtandi and hopefully in the near future Radium-223 Dichloride (Alpharadin) we have many new treatment options available for men with advanced prostate cancer.
Among the many questions we are now faced with is what would happen if we found ways to combine these new treatments? What are the best combinations? We also need to ask what is the best way to sequence these new treatments to maximize their effects? Of course, if we do combine these treatments we will also need to learn how to sequence these combinations to get the best results.
The only way to find these answers is through new, additional clinical trials. Trials that combine these newer treatments and eventually trials that sequence both the drugs and their combinations will be needed to answer these questions.
Putting together and running these trials will take time, money and the willingness of the pharmaceutical companies. Fortunately, we have begun to se